YSYun Ju Sung

Yun Ju Sung

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yun Ju Sung has a total of 990 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Low overlap of plasma and CSF protein quantitative trait loci affects protein discovery for neurological disease

    by Daniel Western, Chengran Yang, Jigyasha Timsina, Menghan Liu, Ciyang Wang, Meghan C. Campbell, Paul Kotzbauer, Joel S. Perlmutter, Suzanne E. Schindler, John C. Morris, et al.

    Plasma protein quantitative trait loci (pQTLs) have been integrated with genetic studies to prioritize proteins implicated in numerous human diseases. However, limited interaction between plasma and the central nervous system decreases the fluid’s relevance for neurological disease. We compared the pQTL landscapes between plasma and cerebrospinal fluid (CSF), detecting widespread differences across fluids that translate to the identification and prioritization of proteins and pathways implicated in neurological disorders. Of almost 5000 CSF and plasma pQTLs, fewer than 30% were present in both fluids, demonstrating the importance of cross-context analyses to understand genetic regulation of protein abundance. We identified 427 associations between proteins and risk of 14 neurological traits, including 249 associations that were not found in previous studies. Only 69 of the associations were consistently detected in both fluids, demonstrating the information gained through the analysis of multiple bodily contexts. We further demonstrated that CSF proteogenomics captures more substantial disease overlap (for example, between Alzheimer’s disease and dementia with Lewy bodies) and captures trait-relevant biology missed in plasma, including cell death and immune response signatures in Alzheimer’s and multiple sclerosis. Through this work, we demonstrated the importance of analyzing less accessible but more trait-relevant contexts to fully understand human disease.


  • Open Access

    Sex‐specific genetic regulation of proteomics in cerebrospinal fluid uncovers genetic causes for sex differences in AD and PD

    by Yun Ju Ju Sung, Anh Do, Soomin Song, Lihua Wang, Daniel Western, Jiseon Kwon, Jigyasha Timsina, Menghan Liu, John P. Budde, Agustin Ruiz, et al.

    Background: Clear sex differences exist in AD and PD. Several studies examined genetic regulations for AD phenotypes and gene expression data in a sex‐specific manner, identifying some differences between males and females. In contrasts, although proteins are final effectors of most physiological pathways and important drug targets, sex‐specific regulations for proteins remain vastly understudied. This study therefore aims to investigate sex‐specific genetic regulation of proteomics in neurologically relevant cerebrospinal fluid (CSF). Methods: We recently identified 3,373 pQTL for 1,886 proteins, many of which were unique to CSF, demonstrating genetic regulation specific to the CSF proteome (Western et al. 2024). Here, we performed a sex‐stratified pQTL (in 1,640 males and 1,713 females, separately) with over 6000 proteins (SomaScan7K) on about 13 million TOPMED imputed autosomal variants. pQTL considered significant at p ‐8 (in cis) and p ‐11 (in trans) in either sex. We subsequently examined relevance of these pQTL with AD and PD through colocalization and protein‐wise association studies (PWAS). Results: We identified 1,684 significant pQTLs (1,047 cis and 637 trans) in either sex within 811 genetic loci for 1,488 proteins. There were 384 pQTLs (22.8%) identified only in one sex (215 in males; 169 in females). The male‐specific pQTLs included locus for SNRPD2 on chromosome 19 (β =‐0.76, p = 4.63×10 ‐8 in males; β=‐0.04, p = 8.38×10 ‐1 in females), whereas the female‐specific pQTLs included locus for IST1 on chr16 (β=0.43, p = 4.40×10 ‐8 in females vs β=‐0.02, p = 7.89×10 ‐1 in males). The PD locus LRRK2 on chr12 regulated several proteins (GRN, GPNMB, ITGB2), enriched in microglia, in males only. In addition, the strongest AD risk APOE region sex‐specifically regulated multiple proteins relevant to AD (PPP3R1, YWHAZ, PPP3CA, amyloidosis‐related NRXN2, VSNL1, and dementia‐related TIMM8A), enriched in neurons. We identified 22 proteins colocalized and associated with AD risk loci (including ACE in females only and TMEM106B in males only). Similarly, 4 proteins linked to PD loci (including ADAM15 in males). Conclusion: By performing sex‐stratified pQTL, we uncovered distinctive sex‐specific genetic regulation of CSF proteome. Our findings complement sex‐aware eQTL from GTEx and provide insights on dissecting the underlying biological causes and mechanisms contributing to sex differences in neurodegeneration.

  • Open Access

    Sex‐specific genetic regulation of proteomics in cerebrospinal fluid uncovers genetic causes for sex differences in AD and PD

    by Yun Ju Ju Sung, Anh Do, Soomin Song, Lihua Wang, Daniel Western, Jiseon Kwon, Jigyasha Timsina, Menghan Liu, John P. Budde, Agustin Ruiz, et al.

    Background: Clear sex differences exist in AD and PD. Several studies examined genetic regulations for AD phenotypes and gene expression data in a sex‐specific manner, identifying some differences between males and females. In contrasts, although proteins are final effectors of most physiological pathways and important drug targets, sex‐specific regulations for proteins remain vastly understudied. This study therefore aims to investigate sex‐specific genetic regulation of proteomics in neurologically relevant cerebrospinal fluid (CSF). Methods: We recently identified 3,373 pQTL for 1,886 proteins, many of which were unique to CSF, demonstrating genetic regulation specific to the CSF proteome (Western et al. 2024). Here, we performed a sex‐stratified pQTL (in 1,640 males and 1,713 females, separately) with over 6000 proteins (SomaScan7K) on about 13 million TOPMED imputed autosomal variants. pQTL considered significant at p ‐8 (in cis) and p ‐11 (in trans) in either sex. We subsequently examined relevance of these pQTL with AD and PD through colocalization and protein‐wise association studies (PWAS). Results: We identified 1,684 significant pQTLs (1,047 cis and 637 trans) in either sex within 811 genetic loci for 1,488 proteins. There were 384 pQTLs (22.8%) identified only in one sex (215 in males; 169 in females). The male‐specific pQTLs included locus for SNRPD2 on chromosome 19 (β =‐0.76, p = 4.63×10 ‐8 in males; β=‐0.04, p = 8.38×10 ‐1 in females), whereas the female‐specific pQTLs included locus for IST1 on chr16 (β=0.43, p = 4.40×10 ‐8 in females vs β=‐0.02, p = 7.89×10 ‐1 in males). The PD locus LRRK2 on chr12 regulated several proteins (GRN, GPNMB, ITGB2), enriched in microglia, in males only. In addition, the strongest AD risk APOE region sex‐specifically regulated multiple proteins relevant to AD (PPP3R1, YWHAZ, PPP3CA, amyloidosis‐related NRXN2, VSNL1, and dementia‐related TIMM8A), enriched in neurons. We identified 22 proteins colocalized and associated with AD risk loci (including ACE in females only and TMEM106B in males only). Similarly, 4 proteins linked to PD loci (including ADAM15 in males). Conclusion: By performing sex‐stratified pQTL, we uncovered distinctive sex‐specific genetic regulation of CSF proteome. Our findings complement sex‐aware eQTL from GTEx and provide insights on dissecting the underlying biological causes and mechanisms contributing to sex differences in neurodegeneration.

  • Open Access

    Integrative Genetic, Proteogenomic, and Multi-omics Analyses Reveal Sex-Biased Causal Genes and Drug Targets in Alzheimer’s Disease

    by Noah Cook, Chenyu Yang, Youjie Zeng, Sathesh K. Sivasankaran, Soomin Song, Lia Talozzi, Daniel Western, Chengran Yang, Yue Liu, Yann Le Guen, et al.

    Sex differences are pervasive in Alzheimer’s disease, but the underlying drivers remain poorly understood. To address this, we performed sex-stratified genome-wide association studies of Alzheimer’s disease in ∼1,000,000 individuals, which we subsequently integrated with proteogenomics datasets from neurological tissues to identify candidate causal genes. We further prioritized genes through additional multi-omics approaches, including quantitative trait locus summary-based mendelian randomization and colocalization. Altogether, we prioritized 125 female-biased and 21 male-biased risk genes. Female-biased pathways included amyloid, neurite, stress, clearance, and immune processes, with genes enriched for microglia and astrocyte expression. Through computational drug repurposing analyses, a set of sex hormone related drugs, converging on Epidermal Growth Factor Receptor ( EGFR ), were uniquely prioritized in women. Finally, we identified Haptoglobin ( HP ) as a female-specific gene, leveraging long-read sequencing approaches to implicate a link to oxidative stress, APOE, and hemoglobin biology. Altogether, our findings provide a portal into sex-specific precision medicine for Alzheimer’s disease.


  • Open Access

    Sex-specific genetic regulation of proteomics in cerebrospinal fluid uncovers genetic causes for sex differences in neurodegeneration

    by Soomin Song, Anh N. Do, Lihua Wang, Gyujin Heo, Jiseon Kwon, Daniel Western, Seung Jin Yang, Jigyasha Timsina, Menghan Liu, John Budde, et al.

    Sex-specific genetic regulation of cerebrospinal fluid (CSF) protein levels may contribute to differential vulnerability to neurodegenerative diseases. To systematically identify sex differences in the genetic regulation of CSF proteome and their link to neurodegeneration, we performed sex-stratified pQTL analysis of 6,361 proteins in 1,713 males and 1,640 females, separately. We identified 1,729 pQTLs significant in either sex. They included 407 sex-specific pQTLs (genetic regulation in only one sex) and 159 sex-biased pQTLs (regulation in both sexes, but with different magnitudes of regulation between sexes). The HLA locus on chromosome 6 and the APOE locus on chromosome 19, two known pleiotropic regions, regulated several proteins in a sex-dependent way. Pathway enrichment revealed several biological processes that were shared and distinctive of sex. Using proteome-wide association study (PWAS) and colocalization, we identified 22 proteins associated and colocalized with AD risk loci. TMEM106B and ACE proteins were identified in only one sex. Four proteins were associated and colocalized with PD risk loci. These findings provide insights into dissecting the underlying mechanisms contributing to sex differences in neurodegeneration.


  • Cerebrospinal fluid proteomic signatures in cognitively normal individuals identify distinct clusters linked to neurodegeneration

    by Dahun Seo, Anh N. Do, Gyujin Heo, Jiseon Kwon, Soomin Song, Catherine Apio, Cheolmin Matthew Lee, Jigyasha Timsina, Katherine Gong, Yike Chen, et al.

    Age and APOE ε4 are major risk factors for Alzheimer’s disease (AD), while sex differences exist in disease prevalence and progression. Cerebrospinal fluid (CSF) proteomics can provide additional insights into brain aging and AD. To examine proteomic changes due to age, sex and apolipoprotein E (APOE) ε4 along with amyloid status before clinical AD occurs, we profiled 6,175 proteins in the CSF from 994 cognitively normal individuals aged 43–91 years. We identified and replicated 2,172 age-associated, 711 sex-associated, 193 APOE ε4-associated and 1,807 amyloid-associated proteins, with extensive overlap suggesting their interplay. These CSF-specific signatures were distinct from those in plasma. Network analysis revealed two proteomic modules—M2 (age-associated, sex-associated and amyloid-associated) and M6 (age-associated and sex-associated)—which were linked to neuropsychiatric and aging-related diseases. Together, our study provides proteomic changes during the early phase of AD, which may help identify new therapeutic targets of AD.


  • Open Access

    European and African ancestry-specific plasma protein-QTL and metabolite-QTL analyses identify ancestry-specific T2D effector proteins and metabolites

    by Chengran Yang, Priyanka Gorijala, Jigyasha Timsina, Lihua Wang, Menghan Liu, Ciyang Wang, William Brock, Yueyao Wang, Fumihiko Urano, Yun Ju Sung, et al.

    In this study, we generated and integrated plasma proteomics and metabolomics with the genotype datasets of over 2300 European (EUR) and 400 African (AFR) ancestries to identify ancestry-specific multi-omics quantitative trait loci (QTLs). In total, we mapped 954 AFR pQTLs, 2848 EUR pQTLs, 65 AFR mQTLs, and 490 EUR mQTLs. We further applied these QTLs to ancestry-stratified type-2 diabetes (T2D) risk to pinpoint key proteins and metabolites underlying the disease-associated genetic loci. Using INTACT that combined trait-imputation and colocalization results, we nominated 270 proteins and 72 metabolites from the EUR set; seven proteins and one metabolite from the AFR set as molecular effectors of T2D risk in an ancestry-stratified manner. Here, we show that the integration of genetic and omic studies of different ancestries can be used to identify distinct effector molecular traits underlying the same disease across diverse ancestral groups.


  • Open Access

    Multi-ancestry genome-wide association analyses incorporating SNP-by-psychosocial interactions identify novel loci for serum lipids

    by Amy R. Bentley, Michael R. Brown, Solomon K. Musani, Karen L. Schwander, Thomas W. Winkler, Mario Sims, Tuomas O. Kilpeläinen, Hugues Aschard, Traci M. Bartz, Lawrence F. Bielak, et al.

    Serum lipid levels, which are influenced by both genetic and environmental factors, are key determinants of cardiometabolic health and are influenced by both genetic and environmental factors. Improving our understanding of their underlying biological mechanisms can have important public health and therapeutic implications. Although psychosocial factors, including depression, anxiety, and perceived social support, are associated with serum lipid levels, it is unknown if they modify the effect of genetic loci that influence lipids. We conducted a genome-wide gene-by-psychosocial factor interaction (G×Psy) study in up to 133,157 individuals to evaluate if G×Psy influences serum lipid levels. We conducted a two-stage meta-analysis of G×Psy using both a one-degree of freedom (1df) interaction test and a joint 2df test of the main and interaction effects. In Stage 1, we performed G×Psy analyses on up to 77,413 individuals and promising associations (P < 10−5) were evaluated in up to 55,744 independent samples in Stage 2. Significant findings (P < 5 × 10−8) were identified based on meta-analyses of the two stages. There were 10,230 variants from 120 loci significantly associated with serum lipids. We identified novel associations for variants in four loci using the 1df test of interaction, and five additional loci using the 2df joint test that were independent of known lipid loci. Of these 9 loci, 7 could not have been detected without modeling the interaction as there was no evidence of association in a standard GWAS model. The genetic diversity of included samples was key in identifying these novel loci: four of the lead variants displayed very low frequency in European ancestry populations. Functional annotation highlighted promising loci for further experimental follow-up, particularly rs73597733 (MACROD2), rs59808825 (GRAMD1B), and rs11702544 (RRP1B). Notably, one of the genes in identified loci (RRP1B) was found to be a target of the approved drug Atenolol suggesting potential for drug repurposing. Overall, our findings suggest that taking interaction between genetic variants and psychosocial factors into account and including genetically diverse populations can lead to novel discoveries for serum lipids.

  • Top Cited Papers

    Large-scale plasma proteomic profiling unveils diagnostic biomarkers and pathways for Alzheimer’s disease

    by Gyujin Heo, Ying Xu, Erming Wang, Muhammad Ali, Hamilton Se-Hwee Oh, Patricia Moran-Losada, Federica Anastasi, Armand González Escalante, Raquel Puerta, Soomin Song, et al.

    Proteomic studies have been instrumental in identifying brain, cerebrospinal fluid and plasma proteins associated with Alzheimer's disease (AD). Here, we comprehensively examined 6,905 aptamers corresponding to 6,106 unique proteins in plasma in more than 3,300 well-characterized individuals to identify new proteins, pathways and predictive models for AD. We identified 416 proteins (294 new) associated with clinical AD status and validated the findings in two external datasets representing more than 7,000 samples. AD-related proteins reflected blood-brain barrier disruption and other processes implicated in AD, such as lipid dysregulation or immune responses. A machine learning model was used to identify a set of seven proteins that were highly predictive of both clinical AD (area under the curve (AUC) of >0.72) and biomarker-defined AD status (AUC of >0.88), which were replicated in multiple external cohorts and orthogonal platforms. These findings underscore the potential of using plasma proteins as biomarkers for the early detection and monitoring of AD and for guiding treatment decisions.


  • Open Access

    Large-scale Plasma Proteomic Profiling Unveils Novel Diagnostic Biomarkers and Pathways for Alzheimer's Disease

    by Carlos Cruchaga, Gyujin Heo, Alvin Thomas, Erming Wang, Hamilton Oh, Muhammad Ali, Jigyasha Timsina, Soomin Song, Menghan Liu, Katherine Gong, et al.

    Alzheimer disease (AD) is a complex neurodegenerative disorder. Proteomic studies have been instrumental in identifying AD-related proteins present in the brain, cerebrospinal fluid, and plasma. This study comprehensively examined 6,905 plasma proteins in more than 3,300 well-characterized individuals to identify new proteins, pathways, and predictive model for AD. With three-stage analysis (discovery, replication, and meta-analysis) we identified 416 proteins (294 novel) associated with clinical AD status and the findings were further validated in two external datasets including more than 7,000 samples and seven previous studies. Pathway analysis revealed that these proteins were involved in endothelial and blood hemostatic (ACHE, SMOC1, SMOC2, VEGFA, VEGFB, SPARC), capturing blood brain barrier (BBB) disruption due to disease. Other pathways were capturing known processes implicated in AD, such as lipid dysregulation (APOE, BIN1, CLU, SMPD1, PLA2G12A, CTSF) or immune response (C5, CFB, DEFA5, FBXL4), which includes proteins known to be part of the causal pathway indicating that some of the identified proteins and pathways are involved in disease pathogenesis. An enrichment of brain and neural pathways (axonal guidance signaling or myelination signaling) indicates that, in fact, blood proteomics capture brain- and disease-related changes, which can lead to the identification of novel biomarkers and predictive models. Machine learning model was employed to identify a set of seven proteins that were highly predictive of both clinical AD (AUC > 0.72) and biomarker-defined AD status (AUC > 0.88), that were replicated in multiple external cohorts as well as with orthogonal platforms. These extensive findings underscore the potential of using plasma proteins as biomarkers for early detection and monitoring of AD, as well as potentially guiding treatment decisions.